Monday, April 15, 2013

Stivarga: New Treatment Options for Colorectal Cancer Patients

"New therapies offer hope for patients living with advanced sickness and highlight the oncology community's ongoing commitment to patients offering not only to be able to improve their quality of life, but in some circumstances even enhances their way of life," says Barry D. Stein, Us president of the Colorectal Cancer Association of Canada. "Stivarga represents another new option for Canadian patients and it is important that this amazing treatment be made available to all Canadians living with metastatic abdominal program melanoma to ensure they have every reasonable probability to fight this sickness." "I want to make the most out of every moment," says Stephen Dunn, level IV colon cancer patient."Treatment options that give patients more time are one more step on an important journey - celebrating another day with my family means everything to me, and also to them."

The data also revealed a survival benefit in the regorafenib arm across nearly all subgroups analyzed.  The most serious adverse reactions are hepatotoxicity, hemorrhage and gastrointestinal perforation.  The most common treatment related adverse reactions are fatigue, hand-foot-skin reaction (HFSR), diarrhea and anorexia. "A metastatic abdominal  melanoma analysis can be frustrating for the patient as well as for themselves associates and close relatives," says Bunnie Schwartz, Co-founder and Us president of Colon Cancer Canada. "New and available treatment options that can prolong a patient's life are critical - the additional time allows the patient to continue to build memories that will be cherished by their families."


"Stivarga's approval in Canada and the united states further decides Bayer as a company dedicated to helping the way of life of patients," Christian Lauterbach, President & CEO of Bayer Inc. in Canada. " Stivarga is an important stage for Bayer in enhancing our oncology profile and offering doctors and patients with new and effective tools to fight melanoma and increase way of life."

About Colon Cancer
Colorectal Cancer (CRC) is the third most common melanoma worldwide, with over 1.2 million circumstances happening every season. It is the second major cause of melanoma deaths in Canada.  An estimated 23,300 Canadians were clinically identified as having abdominal program melanoma this season and 9,200 passed away of it.

Metastatic cancer is melanoma that has distribute from the place where it first started to another place in the program. A growth established by metastatic melanoma cells is known as a metastatic tumour or a metastasis. The process by which melanoma cells distribute to other parts of body is also known as metastasis. Of the patients with abdominal program melanoma, approximately 20,600 have metastatic abdominal program melanoma. mCRC is one of the most competitive types of cancer; however, ongoing analysis and new therapies have prolonged average overall achievements to more than 20 months, an increase that has customized the view of amazing abdominal program melanoma from an acute to a chronic.

About Stivarga
Regorafenib is an oral multi-kinase chemical affecting systems fortumour growth and progression - angiogenesis, oncogenesis and the tumour microenvironment. In preclinical studies, regorafenib stops several angiogenic VEGF receptor tyrosine kinases that be a factor in growth angiogenesis and lymphangiogenesis (the growth of new veins and the the lymphatic program vessels). It also stops various oncogenic and growth microenvironment kinases such as VEGFR 1-3, KIT, RET, PDGFR, and FGFR, which individually and mutually effect upon tumour growth, formation of a stromal microenvironment and disease progression.


Safety and adverse activities were similar to those observed with other tyrosine kinase inhibitors (TKIS) The most frequently observed adverse drugs reactions in patients getting regorafenib were asthenia/fatigue, reduced hunger and diet, appetite and food intake, hand-foot-skin reaction, diarrhea, mucositis, weight loss, infection, hypertension and dysphonia. The most serious adverse drug reactions in patients receiving regorafenib were hepatotoxicity, hemorrhage and gastrointestinal perforation.Regorafenib is also under investigation in metastatic and/or unresectable gastrointestinal stromal tumours (GIST) for patients whose disease has progressed despite prior treatment with imatinib and sunitinib. 

Source: http://bit.ly/9PDs0S

Colopril

2 comments:

  1. This comment has been removed by a blog administrator.

    ReplyDelete
  2. This comment has been removed by a blog administrator.

    ReplyDelete